The 2022 Annual Meeting of the American Society of Clinical Oncology (ASCO) is being held in Chicago from 3-7 June 2022. This report is a compilation of our coverage through the first three days of the 2022 ASCO meeting, and includes a list of the weekend data events we have added into Biomedtracker to date along with commentary on key presentations by our analysts virtually attending the meeting. Additional coverage from the meeting will be added to the database over the next few days and compiled in our post-meeting report.
Table of Contents
- Summary
- About the Author
- Disclaimer
- Event Analysis and Commentary
- Vectibix for Colorectal Cancer (CRC)
- Opdivo for Melanoma
- Enhertu for Breast Cancer
- Jemperli for Solid Tumors
- Teclistamab for Multiple Myeloma (MM)
- Keytruda for Melanoma
- Tecentriq for Small Cell Lung Cancer (SCLC)
- Tiragolumab for Small Cell Lung Cancer (SCLC)
- HLX10 for Small Cell Lung Cancer (SCLC)
- Imbruvica for Chronic Lymphocytic Leukemia (CLL)/Small Cell Lymphocytic Lymphoma (SLL) - NHL
- Venclexta for Acute Myelogenous Leukemia (AML)
- Calquence for Chronic Lymphocytic Leukemia (CLL)/Small Cell Lymphocytic Lymphoma (SLL) - NHL
- Opdivo for Esophageal Cancer
- Magrolimab for Myelodysplastic Syndrome (MDS)
- Trodelvy for Breast Cancer
- Zejula for Pancreatic Cancer
- Mirvetuximab Soravtansine for Ovarian Cancer
- Kisqali for Breast Cancer
- Ibrance for Breast Cancer
- Mektovi for Colorectal Cancer (CRC)
- PTC596 for Sarcoma
- Disitamab Vedotin for Bladder Cancer
- Imbruvica for Mantle Cell Lymphoma - NHL
- CART-ddBCMA (Arcellx) for Multiple Myeloma (MM)
- Orpathys for Renal Cell Cancer (RCC)
- Nimotuzumab for Pancreatic Cancer
- Patritumab Deruxtecan for Breast Cancer
- Rybrevant for Non-Small Cell Lung Cancer (NSCLC)
- Rybrevant for Non-Small Cell Lung Cancer (NSCLC)
- CLN-081 for Non-Small Cell Lung Cancer (NSCLC)
